검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Cabozantinib S-malate |
Overview Company | Exelixis |
Overview Modality | ADC |
Overview Target | Infiltrating Bladder Urothelial Carcinom |
Overview Indication | Differentiated Thyroid Gland Carcinoma; Follicular Variant Thyroid Gland Papillary Carcinoma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Biomarker | Biomarkers and Their Applications in Management of Thyroid Cancers |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | pd |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date.. In the past few years, new drugs made their appearance in the first-line setting of treatment for metastatic renal cell carcinoma (mRCC), and cabozantinib is one among them. The present systematic review aims to point out any evidence published to date about first-line treatment with cabozantinib f… |
Clinical Primary efficacy | ORR 25% |
Clinical ORR | 25% |
Clinical PFS | 5.3 |
Clinical OS | 13 |
Clinical Result source | ClinicalTrials.gov NCT03367741 |
Clinical Data Tier / Score | A · 48 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Cabozantinib S-malate |
Overview Company | Exelixis |
Overview Modality | ADC |
Overview Target | Infiltrating Bladder Urothelial Carcinom |
Overview Indication | Differentiated Thyroid Gland Carcinoma; Follicular Variant Thyroid Gland Papillary Carcinoma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Biomarker | Biomarkers and Their Applications in Management of Thyroid Cancers |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | pd |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date.. In the past few years, new drugs made their appearance in the first-line setting of treatment for metastatic renal cell carcinoma (mRCC), and cabozantinib is one among them. The present systematic review aims to point out any evidence published to date about first-line treatment with cabozantinib f… |
Clinical Primary efficacy | ORR 25% |
Clinical ORR | 25% |
Clinical PFS | 5.3 |
Clinical OS | 13 |
Clinical Result source | ClinicalTrials.gov NCT03367741 |
Clinical Data Tier / Score | A · 48 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
추천 비교
추천 비교